We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
-0.55%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$134M
AUM Growth
-$83.7M
Cap. Flow
-$79.5M
Cap. Flow %
-59.18%
Top 10 Hldgs %
89.42%
Holding
21
New
3
Increased
3
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
CAH icon
Cardinal Health
CAH
+$5.72M
2
ELV icon
Elevance Health
ELV
+$5.42M
3
COR icon
Cencora
COR
+$4.46M
4
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$1.69M
5
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$914K

Top Sells

Rank Stock Value
1
AMAG
AMAG Pharmaceuticals
AMAG
+$16.1M
2
FEIC
FEI COMPANY
FEIC
+$12.7M
3
LPNT
LifePoint Health, Inc.
LPNT
+$12.1M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$11.7M
5
ANIK icon
Anika Therapeutics
ANIK
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 84.33%
2 Industrials 7.34%
3 Financials 7.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAH icon
1
Cardinal Health
CAH
$53.9B
$17.9M 13.34%
230,800
+70,800
+44% +$5.72M
COR icon
2
Cencora
COR
$60.6B
$17.1M 12.74%
212,000
+52,000
+33% +$4.46M
ELV icon
3
Elevance Health
ELV
$81.5B
$17M 12.67%
135,900
+42,000
+45% +$5.42M
SYNH
4
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$9.94M 7.39%
222,875
-63,395
-22% -$2.75M
CRL icon
5
Charles River Laboratories
CRL
$11.2B
$9.88M 7.36%
118,612
-31,000
-21% -$2.6M
GNC
6
DELISTED
GNC Holdings, Inc.
GNC
$9.86M 7.34%
482,955
-199,000
-29% -$4.36M
MRK icon
7
Merck
MRK
$322B
$9.8M 7.3%
164,641
-70,216
-30% -$4.11M
ANIK icon
8
Anika Therapeutics
ANIK
$258M
$9.74M 7.25%
203,493
-209,095
-51% -$10.3M
GTS
9
DELISTED
Triple-S Management Corporation
GTS
$9.43M 7.02%
451,875
-108,235
-19% -$2.42M
TARO
10
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$9.42M 7.01%
85,205
-1,000
-1% -$132K
SUPN icon
11
Supernus Pharmaceuticals
SUPN
$2.59B
$9.39M 6.98%
379,533
-278,000
-42% -$6.29M
PGNX
12
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$1.77M 1.32%
+280,000
New +$1.69M
ICCC icon
13
ImmuCell
ICCC
$101M
$1.3M 0.97%
168,323
– –
BIL icon
14
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$47.1B
$915K 0.68%
+10,000
New +$914K
SHY icon
15
iShares 1-3 Year Treasury Bond ETF
SHY
$25.5B
$850K 0.63%
+10,000
New +$851K
OSUR icon
16
OraSure Technologies
OSUR
$279M
– –
-475,771
Closed -$2.81M
AMAG
17
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-671,585
Closed -$16.1M
INSY
18
DELISTED
Insys Therapeutics, Inc.
INSY
– –
-788,175
Closed -$10.2M
CXRX
19
DELISTED
Concordia International Corp. Common Stock
CXRX
– –
-543,000
Closed -$11.7M
FEIC
20
DELISTED
FEI COMPANY
FEIC
– –
-118,609
Closed -$12.7M
LPNT
21
DELISTED
LifePoint Health, Inc.
LPNT
– –
-185,851
Closed -$12.1M

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $372M AUM
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return

HealthInvest Partners's Q3 2016 Portfolio in Review

As of Q3 2016, HealthInvest Partners held 21 positions worth $134M, down 38% from $218M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

HealthInvest Partners withdrew a net $79.5M in Q3 2016, closing 6 positions and reducing 8 holdings. Its most notable exit was AMAG Pharmaceuticals, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 73% a quarter earlier, followed by Industrials and Financials.

Against the trend, HealthInvest Partners opened a new position in Progenics Pharmaceuticals Inc worth $1.77M.

  • HealthInvest Partners's largest Q3 2016 buy was Progenics Pharmaceuticals Inc: 280,000 shares worth $1.77M.
  • HealthInvest Partners added most to Cardinal Health in Q3 2016, an estimated $5.72M increase.
  • HealthInvest Partners's biggest Q3 2016 reduction was Anika Therapeutics, cutting an estimated $10.3M.
  • HealthInvest Partners fully exited AMAG Pharmaceuticals in Q3 2016, selling an estimated $16.1M.
  • HealthInvest Partners's ten largest holdings make up 89% of its $134M portfolio in Q3 2016.
  • HealthInvest Partners opened 3 new positions and closed 6 in Q3 2016.
  • HealthInvest Partners's portfolio value fell 38% quarter-over-quarter to $134M.

Based on HealthInvest Partners's 13F filing for Q3 2016, filed 24 Oct 2016.